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Abstract
Background: COMP (Cartilage oligomeric matrix protein) is a matrix protein, which is currently studied
as a potential serum marker for cartilage processes in osteoarthritis (OA). The influence of physical
exercise on serum COMP is not fully elucidated.
The objective of the present study was to monitor serum levels of COMP during a randomised controlled
trial of physical exercise vs. standardised rest in individuals with symptomatic and radiographic knee OA.
Methods: Blood samples were collected from 58 individuals at predefined time points before and after
exercise or rest, one training group and one control group. The physical exercise consisted of a one-hour
supervised session twice a week and daily home exercises. In a second supplementary study 7 individuals
were subjected to the same exercise program and sampling of blood was performed at fixed intervals
before, immediately after, 30 and 60 minutes after the exercise session and then with 60 minutes interval
for another five hours after exercise to monitor the short-term changes of serum COMP. COMP was
quantified with a sandwich-ELISA (AnaMar Medical, Lund, Sweden).
Results: Before exercise or rest no significant differences in COMP levels were seen between the groups.
After 60 minutes exercise serum COMP levels increased (p < 0.001). After 60 minutes of rest the serum
levels decreased (p = 0.003). Median serum COMP values in samples obtained prior to exercise or rest at
baseline and after 24 weeks did not change between start and end of the study. In the second study serum
COMP was increased immediately after exercise (p = 0.018) and had decreased to baseline levels after 30
minutes.
Conclusion: Serum COMP levels increased during exercise in individuals with knee OA, whereas levels
decreased during rest. The increased serum COMP levels were normalized 30 minutes after exercise
session, therefore we suggest that samples of blood for analysis of serum COMP should be drawn after at
least 30 minutes rest in a seated position. No increase was seen after a six-week exercise program
indicating that any effect of individualized supervised exercise on cartilage turnover is transient.
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Background
Osteoarthritis (OA) is a disorder of multifactorial origin,
which involves articular cartilage, synovium, subchondral
bone, ligaments and/or the neuromuscular apparatus [1].
OA causes disability, pain and reduced quality of life. Risk
factors for occurrence and progression of knee OA include
age, previous injury, increased body mass index (BMI),
genetic factors and high workload [2]. Studies suggest that
low quadriceps strength increases the risk of OA develop-
ment in the tibiofemoral joint [3]. Exercise is recom-
mended for treatment of OA [4]. Several studies have
shown that increased muscle strength provides joint sta-
bility and reduces pain and disability [5-7]. It is not clear
if physical exercise also affects the properties of joint car-
tilage in vivo [8]. However, a recent study using delayed
gadolinium enhanced magnetic resonance imaging in
patients at high risk of knee OA, suggested increased gly-
cosaminoglycan content in cartilage after exercise [9]. In
vitro studies have shown enhanced production of matrix
components in cartilage explants during cyclic compres-
sion [10,11].
A possible way to identify tissue matrix processes in OA is
by monitoring tissue proteins or their fragments released
into serum [12,13]. Such biomarkers also represent
potential tools for monitoring effects of treatment on the
tissue [14]. One such potential biomarker is cartilage oli-
gomeric matrix protein (COMP). COMP is a five-armed
435 kD non-collagenous protein primarily identified in
cartilage [15,16]. COMP interacts with collagen and is
suggested to have a role in regulating fibril assembly as
well as a structural role for maintaining the mature colla-
gen network [17]. Studies of experimental arthritis have
been used to demonstrate that changes in serum levels of
COMP reflect processes in cartilage [18,19]. Supportive
evidence from human arthritis is also emerging. For
instance, therapeutic interventions which aim at retarding
joint damage, such as blockade of tumour necrosis factor-
alpha in rheumatoid arthritis, normalize serum COMP
levels [20]. In other studies, the feasibility of serum
COMP as a prognostic indicator of future joint damage
and as a marker of ongoing joint damage, e.g. in OA and
rheumatoid arthritis, has been suggested [21-24]. Thus,
although small amounts of COMP are present in other tis-
sues i.e. tendon and synovium, the evidence in favour of
serum COMP being primarily derived from cartilage is
compelling.
The objective of the present intervention was to monitor
serum concentrations of COMP in a randomised control-
led trial of physical exercise in patients with symptomatic
and radiographically verified knee OA [25] to elucidate
how standardised physical activity influences the turnover
of COMP, study 1. In a supplementary small study we
examined the short-term changes of serum-COMP imme-
diately after exercise, study 2.
Methods
Subjects
In study 1 patients aged 36–65 years with symptomatic
radiographically verified knee OA, uni- or bilateral Kell-
gren-Lawrence grade 3 or more, were included in a ran-
domised controlled trial of physical exercise in knee OA.
The clinical results of this study have previously been
reported [25]. Patients were recruited from the Depart-
ment of Radiology at the Halmstad County Hospital in
Sweden. They had been referred to radiographic knee
joint examination due to knee pain by their general prac-
titioner.
Patients with inflammatory joint disorders, previous ante-
rior cruciate ligament injury, or known injury to the
menisci were excluded. Furthermore, patients with hip
symptoms more severe than the knee symptoms (verified
by clinical examination), patients being on the waiting list
for knee replacement expected to be operated within 6
months, or with co-morbidities not allowing exercise were
also excluded. Fifty-eight subjects fulfilled the criteria for
inclusion and were randomised to exercise (n = 29,15
men and 14 women, with median (range) age 55 years
(36–64) and median (range) Body Mass Index (BMI) 28.7
(23.0–43.0)) or rest (n = 29, 14 men and 15 women with
median (range) age 57 years (46–65) and median (range)
BMI 27.9 (22.0–45.0). The exercise group and the control
group did not differ regarding age or BMI.
Blood samples were obtained from all subjects at prede-
fined intervals. At each occasion blood samples were
obtained twice with an hour apart, in total 8 samples dur-
ing study 1. Samples were taken at four different occa-
sions, before intervention at -3 weeks, during intervention
at two time points, 0 and 6 weeks, and after intervention
at 24 weeks. At weeks -3 and 24 both groups were resting
for one hour and at weeks 0 and 6 the exercise group was
exercising and the control group was resting one hour
between sampling of blood. The sampling schedule is out-
lined in figure 1.
All patients in the exercise group followed the exercise
protocol. The program consisted of weight-bearing exer-
cises aimed at increasing postural control, endurance and
strength in the lower extremity. Exercises were performed
at five stations at intensity of ≥ 60% of maximum heart
rate (HRmax). This one-hour supervised, high intensity
session was performed twice a week increasing aerobic
capacity and muscular endurance and strength in the
lower extremities. Home exercises for at least 30 minutes
every day were prescribed for the other days during the six-BMC Musculoskeletal Disorders 2006, 7:98 http://www.biomedcentral.com/1471-2474/7/98
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week intervention period. The protocol has been
described in detail [25].
The control group had no restrictions and were instructed
to continue with their usual daily activities. All patients
had been travelling to the hospital and there was no
standardised rest period before the first serum sample was
drawn. The control group was resting in a chair for one
hour between the blood sampling procedures, figure 1.
We also designed a second, supplementary study to mon-
itor serum COMP with repeated measurements after the
exercise session. Seven patients, who had participated in
the exercise-group in the first study, median (range) age
55 years (51–67) and median (range) BMI 27.2 (24.9–
37.5) were included. The physical exercise consisted of a
one-hour supervised, high intensity session, as performed
in study 1. Blood samples were collected before, immedi-
ately after, 30 and 60 minutes after the exercise session
and then with 60 minutes interval for another five hours.
The patients were told not to exercise 24 hours before
sampling. After the training session they were resting in a
chair in the hospital waiting room until the last serum
sample had been retrieved.
COMP analyses
Venous blood samples were obtained from vena mediana
cubitii. After clotting for 60 minutes at room temperature,
they were centrifuged at 2000 g for 10 minutes at +4°C.
The serum samples were stored at -20°C until all the
serum samples were obtained. The samples were then
stored at -80°C until analysis. Serum COMP levels were
analysed with a sandwich-ELISA (AnaMar Medical, Lund,
Sweden).
Statistical methods and ethical approval
Comparisons between groups and within groups were
performed using Mann-Whitney U test and Wilcoxon
matched pairs test, respectively. A p-value of <0.05 was
considered significant. Informed consent was obtained
from the patients participating in the study. Ethical
approval was obtained from the Research Ethics Commit-
tee, Lund University, Sweden (LU 99–98) and is in com-
pliance with Helsinki Declaration.
Results
Study 1
1. Serum COMP at start of study
At time point -3 weeks, i.e. three weeks before the inter-
vention started, there were no significant differences in
serum COMP levels between the exercise and control
group. Median (range) serum COMP levels were in the
exercise-group 11.03 (6.60–16.52) U/L and in the con-
trol-group 11.29 (6.38–22.11) U/L. In both groups there
was a slight decrease in serum-COMP levels after one hour
of rest (p < 0.001), figure 2.
2. Serum COMP during intervention
Before exercise no significant differences in COMP levels
were seen between the two groups at 0 or at 6 weeks, data
not shown. After 60 minutes of exercise serum COMP lev-
els increased (median increase 1.3 U/L, p < 0.001) at both
time points in the exercise group, figure 3. At time point 0
and 6 the serum levels decreased slightly after one hour
Study design Figure 1
Study design. Blood-sampling procedures during the study from study baseline at -3 weeks to the end of the study at 24 
weeks. Blood samples were obtained before and after 60 minutes exercise/rest at each occasion. The arrows indicates blood-
sampling occasions. Two blood-samples at each occasions, with an hour apart.
Exercise-group rest  exercise  exercise  rest 
Control-group rest  rest  rest  rest 
-3  0 weeks  6 24
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rest in the control group (median decrease 0.6 U/L, p =
0.003 and p = 0.053), data not shown.
3. Serum COMP during the study period and at follow up
At time point 24 weeks, serum COMP levels decreased
after one hour of rest in both groups, p = 0.002 in exercise
group and p = 0.004 in control group, in a similar manner
as at time point – 3 weeks. Serum COMP values did not
differ between start (-3 weeks) and end of the study (24
weeks) in either group (data not shown). Thus the levels
returned to baseline after the dynamic exercise interven-
tion and after resting. Median (range) serum COMP levels
were at the end of the study 10.92 (7.43–15.98) U/L in the
exercise-group and 11.24 (7.28–22.00) U/L in the control
group. The levels did not differ between the groups.
Study 2
Serum COMP after standardised exercise in seven patients recruited 
from the exercise group in study 1
Blood samples were collected before, immediately after,
30 and 60 minutes after the exercise session and then with
60 minutes interval for another five hours. The serum
COMP levels increased immediately after exercise from a
median level of 10.5 U/L to a median level of 11.6 U/L, p
= 0.018, figure 4. The levels then decreased and at 30 min-
utes after the exercise session the levels did not differ sig-
Serum COMP at start of study Figure 2
Serum COMP at start of study. Serum concentration of COMP at week -3, before intervention, in study 1. Each line rep-
resents an individual patient. Horizontal bars show median values for each group.
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nificantly from baseline. As seen in figure 4 insert, the
median level tended to decrease towards baseline levels
during the whole observation period.
Discussion
In this study of patients with knee OA, we could in a
reproducible fashion show that physical activity accord-
ing to a predefined protocol resulted in a significant
increase in the serum levels of COMP. In contrast, resting
in a chair for one hour reduced the serum levels slightly,
but significantly. We did not observe any changes of the
baseline COMP levels over the 24-week period, thus there
appears to be no long-term influence on the turnover of
COMP induced by this physical exercise. To further exam-
ine the changes in serum COMP after exercise we per-
formed a supplementary study with more frequent
measurements to elucidate the kinetics of serum COMP
during the time immediately following the exercise ses-
sion. We found that the serum concentrations rapidly
returned to baseline, figure 4, and the concentrations did
not differ from baseline after 30-minutes rest.
Recently Mündermann and co-workers reported that
moderate walking activity during 30 minutes in healthy
individuals significantly increased serum COMP as meas-
ured by the same assay as the one used in our study [26].
Importantly, in line with the results in the OA patients in
the present study, they found that the serum levels had
returned to baseline after 30 minutes. They also found
that serum COMP decreased during rest in these individ-
uals, also in line with the results of the present study.
Neidhart and co-workers found increasing serum levels of
COMP using another assay in 8 athletes during a mara-
thon run. In these endurance-trained runners serum
COMP was at baseline elevated compared to healthy age-
Serum COMP during intervention Figure 3
Serum COMP during intervention. Serum concentrations of COMP at weeks 0 and 6 in the exercise group in study 1. 
Each line represents an individual patient. Horizontal bars show median values for each sampling occasion.
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and sex-matched controls. The serum levels returned to
baseline within 24–48 hours, which was considerably
slower than in our study possibly because of more
extreme exercise in these physically fit individuals [27].
One possible reason for the changes in serum COMP dur-
ing physical exercise is mobilization of COMP from carti-
lage or other pressure loaded tissues. Increased cartilage
degradation without compensatory increased synthesis
cannot be ruled out. However, since the changes are tran-
sient it is unlikely that the exercise exerts any negative
long-term effects on cartilage.
Another, perhaps more likely reason for the changes could
be modifications of the extra-cartilage turnover of COMP
with more of the protein being transported from the syn-
ovial fluid into the lymphatics and further into the blood
stream during and immediately after exercise.
We have in another study shown a diurnal variation of
serum COMP with stable levels during daytime and with
the lowest levels found at night during bed rest. This is in
line with the results of the present study where decreasing
levels were found during rest [28]. In the study of diurnal
variation a putitative half-life of COMP in serum was cal-
culated to be 7.4 hours.
All patients had been travelling to the hospital and there
was no standardised rest period before the first serum
sample was drawn. This could mean that the observed
decrease of serum levels during rest was due to a return to
baseline after physical activity.
Serum COMP after standardised exercise in seven patients recruited from the exercise group in study 1 Figure 4
Serum COMP after standardised exercise in seven patients recruited from the exercise group in study 1. Serum 
COMP concentrations after a one-hour supervised exercise session in 7 patients, study 2. Each line represents an individual 
patient. The inserted figure shows serum COMP concentration in percent of baseline after a one-hour supervised exercise ses-
sion.
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Conclusion
The changes in serum levels of COMP, are small and do
not compromise the utility of COMP as a biomarker, e.g.
for monitoring treatment effects on the tissue. Thus, we
suggest that samples of blood for analysis of serum COMP
should be drawn after at least 30 minutes rest in a seated
position. This is particularly important if sequential sam-
ples are to be obtained from the same patient. It should be
noted that the information provided in this study pertains
to patients with knee OA. However, since similar findings
were reported for healthy controls it seems reasonable to
adhere to this recommendation for all patients. Finally, it
should be stressed that little information regarding the
influence of exercise on serum concentrations for other
putative biomarkers of cartilage is available. Thus, we sug-
gest that similar studies should be performed for other
markers.
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